QRG Capital Management Inc. Sells 10,459 Shares of CVS Health Corporation $CVS

QRG Capital Management Inc. lowered its holdings in CVS Health Corporation (NYSE:CVS) by 9.7% during the 1st quarter, Holdings Channel reports. The firm owned 97,485 shares of the pharmacy operator’s stock after selling 10,459 shares during the period. QRG Capital Management Inc.’s holdings in CVS Health were worth $7,001,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in CVS. TOWER TRUST & INVESTMENT Co raised its stake in shares of CVS Health by 0.8% during the 4th quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock worth $1,247,000 after purchasing an additional 132 shares during the period. CYBER HORNET ETFs LLC grew its position in CVS Health by 4.1% during the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after buying an additional 134 shares during the period. LS Investment Advisors LLC increased its holdings in CVS Health by 3.9% during the fourth quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock worth $284,000 after buying an additional 135 shares during the last quarter. Moss Adams Wealth Advisors LLC increased its holdings in CVS Health by 4.7% during the fourth quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock worth $239,000 after buying an additional 135 shares during the last quarter. Finally, Northwestern Mutual Investment Management Company LLC raised its position in CVS Health by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock worth $3,219,000 after acquiring an additional 136 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at CVS Health

In related news, Director Larry Robbins sold 1,983,538 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares in the company, valued at $586,842,501.45. This trade represents a 24.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,441,551 shares of company stock worth $323,703,977 over the last ninety days. Insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CVS Health in a report on Friday, May 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of CVS Health in a research report on Thursday, June 11th. DA Davidson boosted their target price on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Royal Bank Of Canada upped their price target on CVS Health from $93.00 to $107.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Finally, Piper Sandler reissued an “overweight” rating and issued a $113.00 price objective on shares of CVS Health in a report on Monday, June 1st. Twenty-one research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, CVS Health presently has an average rating of “Moderate Buy” and a consensus price target of $101.28.

CVS Health Price Performance

CVS Health stock opened at $104.74 on Monday. The stock has a market cap of $133.64 billion, a price-to-earnings ratio of 46.14, a PEG ratio of 1.03 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The business has a 50-day simple moving average of $94.56 and a 200 day simple moving average of $83.31. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $106.15.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter last year, the company posted $2.25 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts forecast that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.